Are the Continuous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients?
Are the Continous Glucose Monitoring Systems Able to Improve Long Term Glycaemic Control in Type 1 Diabetic Patients With Poor Metabolic Control?
Sponsor: Abbott
Listed as NCT00726440, this NA trial focuses on Type 1 Diabetes and remains completed. Sponsored by Abbott, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Sep 2020 — Jan 2021 [monthly]
Completed NA
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2020 [monthly]
Completed NA
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Feb 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abbott
- Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Besançon, France , Corbeil-Essonnes, France , Grenoble, France , Liège, Belgium , Lyon, France , Marseille, France , Montpellier, France , Nancy, France , Nantes, France , Paris, France and 6 more locations